Oseltamivir
- PMID: 19884755
- DOI: 10.4103/0022-3859.57411
Oseltamivir
Abstract
Oseltamivir, a selective neuraminidase enzyme inhibitor, has gained worldwide attention in view of Influenza A (H1N1) pandemic. It is one of the most important drugs effective against the novel influenza virus. Oseltamivir is used for the treatment of uncomplicated acute illness due to influenza infection. Early initiation of treatment with the drug provides greater clinical benefits. The drug can also be effectively used for prophylaxis. Oseltamivir is readily absorbed from the gastrointestinal tract and is converted to the active metabolite- oseltamivir carboxylate, which has a wider distribution in the body. Oseltamivir carboxylate is eliminated in the urine with a half-life of 6-10 h. The drug is generally well-tolerated and does not have many clinically significant drug interactions. Nausea and vomiting are the commonest adverse effects associated with its use. The standard adult dose for treatment is 75 mg twice a day for five days and the dose for prophylaxis is 75 mg once daily for at least seven days following contact with an infected individual. The dose needs to be adjusted in patients with renal failure but no adjustments are required in patients with hepatic impairment. Although most of the influenza virus strains are sensitive to oseltamivir, development of drug resistance may limit the clinical utility of the drug in the future.
Similar articles
-
Oseltamivir boosts 2009 H1N1 virus infectivity in vitro.Biochem Biophys Res Commun. 2009 Dec 25;390(4):1305-8. doi: 10.1016/j.bbrc.2009.10.142. Epub 2009 Oct 29. Biochem Biophys Res Commun. 2009. PMID: 19879239
-
Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme.Antiviral Res. 2011 Sep;91(3):288-91. doi: 10.1016/j.antiviral.2011.06.010. Epub 2011 Jun 22. Antiviral Res. 2011. PMID: 21722670
-
[Drug-resistant influenza viruses: an overview].Nihon Rinsho. 2010 Sep;68(9):1671-8. Nihon Rinsho. 2010. PMID: 20845746 Review. Japanese.
-
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.Antivir Ther. 2010;15(8):1151-9. doi: 10.3851/IMP1678. Antivir Ther. 2010. PMID: 21149922
-
Influenza viruses resistant to neuraminidase inhibitors.Acta Biochim Pol. 2014;61(3):505-8. Epub 2014 Sep 8. Acta Biochim Pol. 2014. PMID: 25195142 Review.
Cited by
-
Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective review.Clin Drug Investig. 2012 Feb 1;32(2):131-7. doi: 10.2165/11595860-000000000-00000. Clin Drug Investig. 2012. PMID: 22149150
-
Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.Inflammopharmacology. 2022 Dec;30(6):1935-1954. doi: 10.1007/s10787-022-01050-7. Epub 2022 Aug 26. Inflammopharmacology. 2022. PMID: 36018432 Free PMC article. Review.
-
Influenza H1N1 infection in a patient with psoriatic arthritis in treatment with Adalimumab: a case report.Clin Rheumatol. 2013 Mar;32 Suppl 1(Suppl 1):S21-3. doi: 10.1007/s10067-010-1415-5. Epub 2010 Mar 5. Clin Rheumatol. 2013. PMID: 20204666 Free PMC article.
-
The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews.PLoS One. 2013;8(4):e60348. doi: 10.1371/journal.pone.0060348. Epub 2013 Apr 2. PLoS One. 2013. PMID: 23565231 Free PMC article. Review.
-
Seasonal Human Influenza: Treatment Options.Curr Treat Options Infect Dis. 2014;6(3):227-244. doi: 10.1007/s40506-014-0019-z. Epub 2014 Jun 25. Curr Treat Options Infect Dis. 2014. PMID: 32288650 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical